QURE

uniQure N.V.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$24.63

Price (1 Year)

$48.72 $14.27

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %52.9 / %30
Non-compliant assets / Total market cap %66.3 / %30
Non-compliant revenue / Total income %55.8 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding.

Website

Analysis (Turkish): QURE Hissesi Caiz mi, Helal mi? uniQure N.V. Katılım Analizi